Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics
Dublin, July 09, 2026 (GLOBE NEWSWIRE) -- The "Postoperative Pain - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The "Postoperative Pain - Pipeline Insight, 2026" report offers critical insights into over 40 companies and 50 pipeline drugs shaping the postoperative pain landscape. It features comprehensive profiles of drugs in various phases, from clinical to nonclinical stages, categorized by product type, development stage, administration route, and molecule type, including inactive pipeline products.
Postoperative Pain: Overview
Postoperative pain is a result of tissue damage and inflammation following surgery, involving neurological and psychological factors. Effective management is vital for recovery, as unmanaged pain can delay healing and may lead to chronic conditions. Acute pain post-surgery is temporary, while chronic pain can last over three months in a significant percentage of patients.
Pain management techniques include multimodal analgesia, where a combination of drugs provides better pain relief with fewer side effects than a single agent, and opioid analgesia, commonly featuring morphine, hydromorphone, and fentanyl.
The report highlights detailed scenarios and prospects in postoperative pain, including a thorough assessment of commercial and clinical aspects, drug mechanisms, clinical studies, and related activities such as licensing and acquisitions.
Report Highlights
The report outlines ongoing efforts of companies and academics in overcoming challenges and exploring new opportunities in postoperative pain R&D with novel treatment approaches.
Postoperative Pain Emerging Drugs Chapters
This section provides detailed analysis of drugs in different clinical development stages, such as Phase III, II, I, and preclinical phases, and covers clinical trials, pharmacological actions, and recent updates.
Postoperative Pain Emerging Drugs:
Postoperative Pain: Therapeutic Assessment
The report provides insights into drugs segregated by key parameters:
Postoperative Pain: Pipeline Development Activities
Insights into therapeutic candidates in development and analysis of activities like collaborations, mergers, and licensing are included.
Postoperative Pain Report Insights
Key Questions
Includes a focus on the number of companies, drugs under development, key collaborations, and trends in overcoming existing therapy limitations.
Key Players
Key Products
Key Topics Covered:
Introduction
Executive Summary
Postoperative Pain: Overview
Pipeline Therapeutics
Therapeutic Assessment
Postoperative Pain- Analytical Perspective
Late Stage Products (Phase III)
PF614: Ensysce Biosciences
Mid Stage Products (Phase II)
ATX101: Allay Therapeutics
Early Stage Products (Phase I
GB-6002: G2GBIO
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Postoperative Pain Key Companies
Postoperative Pain Key Products
Postoperative Pain- Unmet Needs
Postoperative Pain- Market Drivers and Barriers
Postoperative Pain- Future Perspectives and Conclusion
Postoperative Pain Analyst Views
Postoperative Pain Key Companies
Appendix
List of Tables
Table 1 Total Products for Postoperative Pain
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Preclinical and Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Postoperative Pain
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4q0wg0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.